Product Description
Hanmi Company Limited is developing Mosapride as a treatment for irritable bowel syndrome without diarrhea. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01505777)
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | China | Dominican Republic | Egypt | India | Japan | Korea | Lebanon | Mexico | Pakistan | Philippines | Sri Lanka | Taiwan | Thailand | Ukraine | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Yabao Pharmaceutical Group
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Gastroparesis|Type 2 Diabetes|Ileus|Irritable Bowel Syndrome|Constipation|Gastroesophageal Reflux|Esophagitis, Peptic
Phase 3: Ileus|Gastrointestinal Cancer
Phase 2: Irritable Bowel Syndrome|Diarrhea
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2400088624 | N/A |
Recruiting |
Constipation |
2026-12-31 |
|
ChiCTR2400082798 | N/A |
Not yet recruiting |
Dyspepsia |
2024-12-01 |
|
COA.MURA2021/328 | N/A |
Unknown status |
Ileus|Colorectal Cancer |
2023-07-31 |
|
ChiCTR2100054269 | N/A |
Recruiting |
Dyspepsia |
2022-12-31 |